组蛋白 H3 赖氨酸过度甲基化是患者来源异种移植（PDX）小鼠模型中三种主要软组织肉瘤的常见分子改变。
Over-methylation of Histone H3 Lysines Is a Common Molecular Change Among the Three Major Types of Soft-tissue Sarcoma in Patient-derived Xenograft (PDX) Mouse Models.
机构信息
AntiCancer Inc, San Diego, CA, U.S.A.
Department of Surgery, University of California San Diego, La Jolla, CA, U.S.A.
出版信息
Cancer Genomics Proteomics. 2021 Nov-Dec;18(6):715-721. doi: 10.21873/cgp.20292.
Abstract
BACKGROUND/AIM: Sarcomas are considered a heterogeneous disease with incomplete understanding of its molecular basis. In the present study, to further understand general molecular changes in sarcoma, patient-derived xenograft (PDX) mouse models of the three most common soft-tissue sarcomas: myxofibrosarcoma, undifferentiated pleomorphic sarcoma (UPS) and liposarcoma were established and the methylation status of histone H3 lysine marks was studied.
MATERIALS AND METHODS
Immunoblotting and immunohistochemical staining were used to quantify the extent of methylation of histone H3K4me3 and histone H3K9me3.
RESULTS
In all 3 sarcoma types in PDX models, histone H3K4me3 and H3K9me3 were found highly over-methylated compared to normal muscle tissue.
CONCLUSION
Histone H3 lysine over-methylation may be a general basis of malignancy of the major sarcoma types.
摘要
背景/目的：肉瘤被认为是一种具有异质性的疾病，其分子基础尚未完全了解。在本研究中，为了进一步了解肉瘤的一般分子变化，建立了三种最常见的软组织肉瘤：黏液纤维肉瘤、未分化多形性肉瘤（UPS）和脂肪肉瘤的患者来源异种移植（PDX）小鼠模型，并研究了组蛋白 H3 赖氨酸标记的甲基化状态。
材料和方法
使用免疫印迹和免疫组织化学染色来定量组蛋白 H3K4me3 和组蛋白 H3K9me3 的甲基化程度。
结果
在 PDX 模型中的所有 3 种肉瘤类型中，与正常肌肉组织相比，组蛋白 H3K4me3 和 H3K9me3 被发现高度过度甲基化。
结论
组蛋白 H3 赖氨酸过度甲基化可能是主要肉瘤类型恶性肿瘤的一般基础。
相似文献
1
Over-methylation of Histone H3 Lysines Is a Common Molecular Change Among the Three Major Types of Soft-tissue Sarcoma in Patient-derived Xenograft (PDX) Mouse Models.
Cancer Genomics Proteomics. 2021 Nov-Dec;18(6):715-721. doi: 10.21873/cgp.20292.
2
Extent and Instability of Trimethylation of Histone H3 Lysine Increases With Degree of Malignancy and Methionine Addiction.
Cancer Genomics Proteomics. 2022 Jan-Feb;19(1):12-18. doi: 10.21873/cgp.20299.
3
Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing.
Mol Cancer Ther. 2019 Jun;18(6):1168-1178. doi: 10.1158/1535-7163.MCT-18-1045. Epub 2019 Apr 8.
4
Labeling the Stroma of a Patient-Derived Orthotopic Xenograft (PDOX) Mouse Model of Undifferentiated Pleomorphic Soft-Tissue Sarcoma With Red Fluorescent Protein for Rapid Non-Invasive Imaging for Drug Screening.
J Cell Biochem. 2017 Feb;118(2):361-365. doi: 10.1002/jcb.25643. Epub 2016 Jul 12.
5
Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts.
BMC Cancer. 2019 Jul 22;19(1):724. doi: 10.1186/s12885-019-5872-1.
6
Histone H3 lysine 4 methyltransferase is required for facultative heterochromatin at specific loci.
BMC Genomics. 2019 May 8;20(1):350. doi: 10.1186/s12864-019-5729-7.
7
Detection of Metastasis in a Patient-derived Orthotopic Xenograft (PDOX) Model of Undifferentiated Pleomorphic Sarcoma with Red Fluorescent Protein.
Anticancer Res. 2019 Jan;39(1):81-85. doi: 10.21873/anticanres.13082.
8
Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape.
Science. 2016 May 13;352(6287):844-9. doi: 10.1126/science.aac7272.
9
Histone methylation status of H3K4me3 and H3K9me3 under methionine restriction is unstable in methionine-addicted cancer cells, but stable in normal cells.
Biochem Biophys Res Commun. 2020 Dec 17;533(4):1034-1038. doi: 10.1016/j.bbrc.2020.09.108. Epub 2020 Oct 3.
10
Pdx-1 links histone H3-Lys-4 methylation to RNA polymerase II elongation during activation of insulin transcription.
J Biol Chem. 2005 Oct 28;280(43):36244-53. doi: 10.1074/jbc.M505741200. Epub 2005 Sep 1.
引用本文的文献
1
Methionine Dependency and Restriction in Cancer: Exploring the Pathogenic Function and Therapeutic Potential.
Pharmaceuticals (Basel). 2025 Apr 28;18(5):640. doi: 10.3390/ph18050640.
2
Elevated-c-MYC-expressing Fibrosarcoma Cells With Acquired Gemcitabine Resistance Remain Sensitive to Recombinant Methioninase: A Potential Clinical Strategy for a Recalcitrant Disease.
Cancer Diagn Progn. 2025 Jan 3;5(1):8-14. doi: 10.21873/cdp.10405. eCollection 2025 Jan-Feb.
3
Synergistic Eradication of Fibrosarcoma With Acquired Ifosfamide Resistance Using Methionine Restriction Combined With Ifosfamide in Nude-mouse Models.
In Vivo. 2025 Jan-Feb;39(1):120-126. doi: 10.21873/invivo.13809.
4
Targeting Methionine Addiction Combined With Low-dose Irinotecan Arrested Colon Cancer in Contrast to High-dose Irinotecan Alone, Which Was Ineffective, in a Nude-mouse Model.
In Vivo. 2024 May-Jun;38(3):1058-1063. doi: 10.21873/invivo.13539.
5
Extensive Shrinkage and Long-term Stable Disease in a Teenage Female Patient With High-grade Glioma Treated With Temozolomide and Radiation in Combination With Oral Recombinant Methioninase and a Low-methionine Diet.
In Vivo. 2024 May-Jun;38(3):1459-1464. doi: 10.21873/invivo.13591.
6
Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy Selection.
Cancers (Basel). 2024 Jan 8;16(2):271. doi: 10.3390/cancers16020271.
7
Asymmetric and symmetric protein arginine methylation in methionine-addicted human cancer cells.
PLoS One. 2023 Dec 22;18(12):e0296291. doi: 10.1371/journal.pone.0296291. eCollection 2023.
8
The Combination of Methioninase and Ethionine Exploits Methionine Addiction to Selectively Eradicate Osteosarcoma Cells and Not Normal Cells and Synergistically Down-regulates the Expression of .
Cancer Genomics Proteomics. 2023 Dec;20(6suppl):679-685. doi: 10.21873/cgp.20415.
9
Recombinant-methioninase-producing Instilled in the Microbiome Inhibits Triple-negative Breast Cancer in an Orthotopic Cell-line Mouse Model.
Cancer Diagn Progn. 2023 Nov 3;3(6):649-654. doi: 10.21873/cdp.10267. eCollection 2023 Nov-Dec.
10
Recombinant Methioninase Lowers the Effective Dose of Regorafenib Against Colon-Cancer Cells: A Strategy for Widespread Clinical Use of a Toxic Drug.
Cancer Diagn Progn. 2023 Nov 3;3(6):655-659. doi: 10.21873/cdp.10268. eCollection 2023 Nov-Dec.
本文引用的文献
1
Oral-recombinant Methioninase Converts an Osteosarcoma from Docetaxel-resistant to -Sensitive in a Clinically-relevant Patient-derived Orthotopic-xenograft (PDOX) Mouse Model.
Anticancer Res. 2021 Apr;41(4):1745-1751. doi: 10.21873/anticanres.14939.
2
Lipid remodeling in response to methionine stress in MDA-MBA-468 triple-negative breast cancer cells.
J Lipid Res. 2021;62:100056. doi: 10.1016/j.jlr.2021.100056. Epub 2021 Feb 26.
3
Combination Methionine-methylation-axis Blockade: A Novel Approach to Target the Methionine Addiction of Cancer.
Cancer Genomics Proteomics. 2021 Mar-Apr;18(2):113-120. doi: 10.21873/cgp.20246.
4
Sensing and Signaling of Methionine Metabolism.
Metabolites. 2021 Jan 31;11(2):83. doi: 10.3390/metabo11020083.
5
Histone methylation status of H3K4me3 and H3K9me3 under methionine restriction is unstable in methionine-addicted cancer cells, but stable in normal cells.
Biochem Biophys Res Commun. 2020 Dec 17;533(4):1034-1038. doi: 10.1016/j.bbrc.2020.09.108. Epub 2020 Oct 3.
6
Recombinant Methioninase Combined With Tumor-targeting A1-R Induced Regression in a PDOX Mouse Model of Doxorubicin-resistant Dedifferentiated Liposarcoma.
Anticancer Res. 2020 May;40(5):2515-2523. doi: 10.21873/anticanres.14222.
7
Methionine Dependence of Cancer.
Biomolecules. 2020 Apr 8;10(4):568. doi: 10.3390/biom10040568.
8
Combination of oral recombinant methioninase and decitabine arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma patient-derived orthotopic xenograft mouse model.
Biochem Biophys Res Commun. 2020 Feb 26;523(1):135-139. doi: 10.1016/j.bbrc.2019.12.024. Epub 2019 Dec 12.
9
The combination of oral-recombinant methioninase and azacitidine arrests a chemotherapy-resistant osteosarcoma patient-derived orthotopic xenograft mouse model.
Cancer Chemother Pharmacol. 2020 Feb;85(2):285-291. doi: 10.1007/s00280-019-03986-0. Epub 2019 Nov 8.
10
Patient-derived orthotopic xenograft models of sarcoma.
Cancer Lett. 2020 Jan 28;469:332-339. doi: 10.1016/j.canlet.2019.10.028. Epub 2019 Oct 19.
Zotero 插件